Physician profile
Peter A Saway
NPI 1417932849
$166,265.36
in general payments reported to CMS, 2019-2025
34 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $26K · 2021: $16K · 2022: $7,784 · 2023: $4,530 · 2024: $12K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $11K · Travel and Lodging: $4,210 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,569.00 |
| Food and Beverage | $11,493.52 |
| Travel and Lodging | $4,209.78 |
| Education | $397.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109,393.65 | 2019-2025 | Evenity, Enbrel, Otezla |
| Radius Health, INC. | $19,608.82 | 2019-2024 | Tymlos |
| Horizon Therapeutics Plc | $15,364.65 | 2019-2022 | |
| Abbvie INC. | $5,499.40 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,245.57 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,995.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,541.03 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $1,432.31 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $1,410.15 | 2019-2025 | Orencia |
| Pfizer INC. | $1,357.21 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $835.49 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $713.23 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $712.80 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $646.71 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $471.62 | 2022-2025 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.59 | 2020-2025 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $394.30 | 2021-2025 | Strensiq |
| Genentech USA, INC. | $300.57 | 2019-2025 | Gazyva, Actemra |
| Medexus Pharma, INC. | $285.85 | 2019-2020 | |
| Genzyme Corporation | $270.91 | 2023-2025 | |
| Pacira Therapeutics, INC. | $252.07 | 2019-2021 | |
| Sobi, INC | $210.02 | 2019-2024 | |
| Organon LLC | $200.13 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Fresenius Kabi USA, LLC | $147.66 | 2023-2024 | Idacio |
| Celgene Corporation | $140.31 | 2019 | |
| Mallinckrodt Enterprises LLC | $110.49 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $85.02 | 2021-2023 | |
| Sandoz INC. | $80.06 | 2023-2025 | Hyrimoz |
| Pacira Pharmaceuticals Incorporated | $59.84 | 2023-2024 | Zilretta |
| Takeda Pharmaceuticals U.S.A., INC. | $24.10 | 2022 | |
| Medtronic, INC. | $17.89 | 2022 | |
| Genentech, INC. | $14.29 | 2023 | Actemra |
| Ferring Pharmaceuticals INC. | $12.92 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Saway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.